Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial
Hydroxytyrosol (HT) plays a significant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled crossover trial determined the effect in healthy v...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2017-01-01
|
| Series: | Oxidative Medicine and Cellular Longevity |
| Online Access: | http://dx.doi.org/10.1155/2017/2473495 |
| id |
doaj-247423b463224c6897505f09db1b79b2 |
|---|---|
| record_format |
Article |
| spelling |
doaj-247423b463224c6897505f09db1b79b22020-11-25T01:11:52ZengHindawi LimitedOxidative Medicine and Cellular Longevity1942-09001942-09942017-01-01201710.1155/2017/24734952473495Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover TrialCarmela Colica0Laura Di Renzo1Domenico Trombetta2Antonella Smeriglio3Sergio Bernardini4Giorgia Cioccoloni5Renata Costa de Miranda6Paola Gualtieri7Paola Sinibaldi Salimei8Antonino De Lorenzo9CNR, IBFM UOS of Germaneto, University “Magna Graecia” of Catanzaro, Campus “Salvatore Venuta”, 88100 Germaneto, Catanzaro, ItalySection of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno d’Alcontres 31, Messina, ItalyDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno d’Alcontres 31, Messina, ItalyDivision of Clinical Biochemistry and Clinical Molecular Biology, University of Rome Tor Vergata, Rome, ItalyPhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyPhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyPhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalySection of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalySection of Clinical Nutrition and Nutrigenomics, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyHydroxytyrosol (HT) plays a significant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled crossover trial determined the effect in healthy volunteers of two gastroresistant capsules containing 15 mg/day of HT, for a 3-week period (HTT). Evaluation of nutritional status, serum metabolites, oxidative stress biomarkers, and gene expression of 9 genes related to oxidative stress, inflammation, and CVDs was performed. Oxidation biomarkers like thiol group (p=0.001), total antioxidant status (TAS) (p=0.001), superoxide dismutase 1 (SOD1) (2−ΔΔCt = 3.7), and plasma concentration of HT (2.83 μg·mL−1) were significantly increased, while nitrite (p=0.001), nitrate (p=0.001), and malondialdehyde (MDA) (p=0.02) were drastically reduced after HTT. A significant reduction of body fat mass percentage (p=0.01), suprailiac skinfold (p=0.01), and weight (p=0.04; Δ% = −0.46%) was observed after HTT. This study shows that regular intake of 15 mg/day of HT changed body composition parameters and modulated the antioxidant profile and the expression of inflammation and oxidative stress-related genes. However, it is advisable to personalize HT doses in order to exert its health benefits in CVD prevention and protection of LDL-C particles from oxidative damage. This trial is registered with ClinicalTrials.gov NCT01890070.http://dx.doi.org/10.1155/2017/2473495 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Carmela Colica Laura Di Renzo Domenico Trombetta Antonella Smeriglio Sergio Bernardini Giorgia Cioccoloni Renata Costa de Miranda Paola Gualtieri Paola Sinibaldi Salimei Antonino De Lorenzo |
| spellingShingle |
Carmela Colica Laura Di Renzo Domenico Trombetta Antonella Smeriglio Sergio Bernardini Giorgia Cioccoloni Renata Costa de Miranda Paola Gualtieri Paola Sinibaldi Salimei Antonino De Lorenzo Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial Oxidative Medicine and Cellular Longevity |
| author_facet |
Carmela Colica Laura Di Renzo Domenico Trombetta Antonella Smeriglio Sergio Bernardini Giorgia Cioccoloni Renata Costa de Miranda Paola Gualtieri Paola Sinibaldi Salimei Antonino De Lorenzo |
| author_sort |
Carmela Colica |
| title |
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial |
| title_short |
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial |
| title_full |
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial |
| title_fullStr |
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial |
| title_full_unstemmed |
Antioxidant Effects of a Hydroxytyrosol-Based Pharmaceutical Formulation on Body Composition, Metabolic State, and Gene Expression: A Randomized Double-Blinded, Placebo-Controlled Crossover Trial |
| title_sort |
antioxidant effects of a hydroxytyrosol-based pharmaceutical formulation on body composition, metabolic state, and gene expression: a randomized double-blinded, placebo-controlled crossover trial |
| publisher |
Hindawi Limited |
| series |
Oxidative Medicine and Cellular Longevity |
| issn |
1942-0900 1942-0994 |
| publishDate |
2017-01-01 |
| description |
Hydroxytyrosol (HT) plays a significant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled crossover trial determined the effect in healthy volunteers of two gastroresistant capsules containing 15 mg/day of HT, for a 3-week period (HTT). Evaluation of nutritional status, serum metabolites, oxidative stress biomarkers, and gene expression of 9 genes related to oxidative stress, inflammation, and CVDs was performed. Oxidation biomarkers like thiol group (p=0.001), total antioxidant status (TAS) (p=0.001), superoxide dismutase 1 (SOD1) (2−ΔΔCt = 3.7), and plasma concentration of HT (2.83 μg·mL−1) were significantly increased, while nitrite (p=0.001), nitrate (p=0.001), and malondialdehyde (MDA) (p=0.02) were drastically reduced after HTT. A significant reduction of body fat mass percentage (p=0.01), suprailiac skinfold (p=0.01), and weight (p=0.04; Δ% = −0.46%) was observed after HTT. This study shows that regular intake of 15 mg/day of HT changed body composition parameters and modulated the antioxidant profile and the expression of inflammation and oxidative stress-related genes. However, it is advisable to personalize HT doses in order to exert its health benefits in CVD prevention and protection of LDL-C particles from oxidative damage. This trial is registered with ClinicalTrials.gov NCT01890070. |
| url |
http://dx.doi.org/10.1155/2017/2473495 |
| work_keys_str_mv |
AT carmelacolica antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT lauradirenzo antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT domenicotrombetta antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT antonellasmeriglio antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT sergiobernardini antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT giorgiacioccoloni antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT renatacostademiranda antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT paolagualtieri antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT paolasinibaldisalimei antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial AT antoninodelorenzo antioxidanteffectsofahydroxytyrosolbasedpharmaceuticalformulationonbodycompositionmetabolicstateandgeneexpressionarandomizeddoubleblindedplacebocontrolledcrossovertrial |
| _version_ |
1725169247882051584 |